Serotonin's Role in Alcohol Use Disorder: Implications for Treatment

Serotonin's Influence on Alcohol Use Disorder

Recent research underscores serotonin's (5-hydroxytryptamine; 5-HT) significant role in alcohol use disorder (AUD), particularly its involvement in mood regulation, impulse control, and the disorder's heterogeneity. Dysregulation of central 5-HT function is linked to AUD and comorbid conditions like depression. This review, published on June 22, 2026, in OpenAlex, emphasizes the complex interplay between serotonin and AUD, suggesting that serotonergic pathways could be pivotal in developing targeted treatments.

Mechanisms Underlying Serotonin and AUD

Alterations in serotonin function, influenced by stress and genetic variations in serotonergic genes such as TPH2 and SLC6A4, may heighten individual vulnerability to AUD. Research indicates that reduced 5-HT activity is associated with an increased risk of developing AUD, particularly Cloninger’s type II, characterized by early onset and antisocial behaviors. Animal studies support these findings, with Tph2-deficient mice and alcohol-preferring rats displaying increased ethanol consumption and reduced serotonergic activity, respectively.

Policy and Research Implications

The potential for serotonergic psychedelic-assisted therapies in treating AUD is gaining attention, especially given the limited efficacy of selective 5-HT reuptake inhibitors (SSRIs) in severe cases. These therapies may work by activating 5-HT 2A receptors in the prefrontal cortex, a region often dysfunctional in AUD. The review calls for improved stratification of AUD subtypes and the identification of 5-HT-related biomarkers to inform personalized therapeutic strategies.

Risks and Unknowns

While the promise of serotonergic psychedelics in AUD treatment is compelling, it is not without risks. The heterogeneity of AUD means that treatment responses can vary significantly among individuals. Additionally, the long-term effects and safety of psychedelic-assisted therapies remain under-researched, necessitating cautious advancement in clinical trials and therapeutic applications.

Future Directions in AUD Treatment

Moving forward, the integration of serotonergic insights into AUD treatment could revolutionize therapeutic approaches. Researchers and clinicians must focus on validating biomarkers and stratifying AUD subtypes to enhance treatment efficacy. The evolving landscape of psychedelic research offers a promising avenue, but rigorous clinical trials are essential to establish safety and effectiveness.